Last reviewed · How we verify
NCT03947294: ICALIC2
The ICALIC 2 International Multicentric Study
trial testing Q-NRG® in Cancer in 137 participants. Terminated before completion.
2 June 2021
Quick facts
| Lead sponsor | Prof. Claude Pichard |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 137 |
| Start date | 7 May 2019 |
| Primary completion | 2 June 2021 |
| Estimated completion | 2 June 2021 |
| Sites | 1 location across Switzerland |
Drugs / interventions tested
- Q-NRG®
Conditions studied
- Cancer — all drugs for Cancer →
- Surgery — all drugs for Surgery →
- Hemodialysis — all drugs for Hemodialysis →
Sponsor
Prof. Claude Pichard
Who can join
18 and older, any sex, with Cancer or Surgery. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Clinicians need to measure energy expenditure (EE) by indirect calorimetry (IC) to optimize nutritional support for a better clinical outcome, especially in patients with chronic conditions or with high risk of under- and over- feeding. However, IC is rarely used in clinical routine because the devices currently on the market are of tedious use, imprecise and expensive. An easy-to-use, accurate and inexpensive IC device (Q-NRG® CE marking n°MED 9811) has been developed to meet specifications made by and for clinicians. The ease of use of this new IC device has been first evaluated in mechanical ventilation mode. This second phase aims at evaluating the ease of use, the stability and the feasibility of the measurements with this new IC device in canopy and face mask modes for spontaneously breathing adult patients.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Clinical evaluation of the new indirect calorimeter in canopy and face mask mode for energy expenditure measurement in spontaneously breathing patients.
Dupertuis YM, Delsoglio M, Hamilton-James K, Berger MM, et al · · 2022 · cited 7× · PMID 35671611 · DOI 10.1016/j.clnu.2022.05.018
Verify or expand the search:
- PubMed search for NCT03947294
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cancer
Currently open trials in the same condition.
- NCT07390045 — Exercise and Cognitive Rehabilitation Interventions for Older Cancer Survivors · NA · recruiting
- NCT07528547 — Hypersight and Ethos In Pediatric Radiotherapy · NA · recruiting
- NCT07481890 — Feasibility and Efficacy of the EMDR Toolbox Method in Cancer Patients. · NA · recruiting
- NCT07402057 — Implementation and Evaluation of a Program Aimed at Facilitating Palliative Care Conversations · NA · recruiting
- NCT07305740 — On-Trac: An Online Intervention for Cancer Survivors Managing Anxiety · NA · recruiting
Other Prof. Claude Pichard trials
Trials by the same sponsor.
- NCT04504799 — Validation of the New HAG-B19 Scale for Measuring Lean and Fat Body Masse · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03947294 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Prof. Claude Pichard
- Last refreshed: 22 November 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03947294.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing